Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial

Cetuximab (Cetux)/Bevacizumab (Bev) treatments have shown considerably survival benefits for patients with metastatic colorectal cancer (mCRC) in the last decade. But they are costly. Currently, no data is available on the health economic implications of testing for extended RAS wild-type (wt) prior...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jing, Zhao, Rongce, Wen, Feng, Zhang, Pengfei, Tang, Ruilei, Chen, Hongdou, Zhang, Jian, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058788/
https://www.ncbi.nlm.nih.gov/pubmed/27399059
http://dx.doi.org/10.1097/MD.0000000000003762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058788/
https://www.ncbi.nlm.nih.gov/pubmed/27399059
http://dx.doi.org/10.1097/MD.0000000000003762

Ejemplares similares